Seeking Alpha

Wedbush ups Endocyte (ECYT) price target to $20 from $16 citing future cash flows from potential...

Wedbush ups Endocyte (ECYT) price target to $20 from $16 citing future cash flows from potential cancer drug Vintafolide which is pending approval in Europe. Baird upgraded the stock earlier in the week with similar comments. Shares +1.9% premarket. 
Comments (1)
  • Bill Swiggart
    , contributor
    Comments (142) | Send Message
     
    Nice upwelling from small catalyst.
    27 Mar 2013, 12:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|